Somatotropin delivery to farmed animals

Advanced Drug Delivery Reviews

Volumn 38, Issue 2, 1999, Pages 151-165

  Foster, Todd P ^a  

^a PFIZER INC   (United States)

Author keywords

Bovine; Drug delivery; Drug development; Formulations; Growth hormone; Porcine; Stability

Indexed keywords

AGRICULTURE; BIOCHEMISTRY; BIOLOGY; COST EFFECTIVENESS; ENZYME KINETICS; FARMS; HORMONES; IMPLANTS (SURGICAL); PH; SOLUBILITY;

DRUG DEVELOPMENT; FARMED ANIMALS; GROWTH HORMONE; PH DEPENDENT SOLUBILITY; PHYSICOCHEMICAL PROPERTIES; PORCINE; SOMATOTROPIN DELIVERY;

CONTROLLED DRUG DELIVERY;

DRUG VEHICLE; EXCIPIENT; GROWTH HORMONE;

ANALYTIC METHOD; ANIMAL; CATTLE; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUTION; DRUG STABILITY; FOOD SAFETY; IMPLANT; MARKET; MILK PRODUCTION; NONHUMAN; OSMOSIS; PH; PHYSICAL CHEMISTRY; POLITICS; PRIORITY JOURNAL; REVIEW; SOCIAL ASPECT; SUSPENSION; SWINE;

EID: 0033059867     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00014-9     Document Type: Article

References (141)

1. Bauman D.E., Vernon R.G. Effects of exogenous bovine somatotropin on lactation. Annu. Rev. Nutr. 13:1993;1437-14361.
2. Stanisiewski E.P., McAllister J.F., Ash K.A., Taylor V.N., Kratzer D.D., Lauderdale J.W. Production performance of dairy cattle administered recombinantly derived bovine somatotropin (USAN, Somavubove) daily: a dose range study. Domest. Anim. Endocrinol. 11:(3):1994;239-260.
3. Fronk T.J., Peel C.J., Bauman D.E., Gorewit R.C. Comparison of different patterns of exogenous growth hormone adminstration on milk production in Holstein cows. J. Anim. Sci. 57:(3):1983;699-705.
4. Moseley W.M., Paulissen J.B., Goodwin M.C., Alaniz G.R., Claflin W.H. Recombinant bovine somatotropin improves growth performance in finishing beef steers. J. Anim. Sci. 70:1992;412-425.
5. Bauman D.E. Bovine somatotropin: review of an emerging animal technology. J. Dairy Sci. 75:1992;3432-3451.
6. Ropp K.L. New animal drug increases milk production. FDA Consum. 28:(4):1994;24.
7. Machlin L.J. Effect of growth hormone on milk production and feed utilization in dairy cows. J. Dairy Sci. 56:1973;575-580.
8. Peel C.J., Bauman D.E., Gorewit R.C., Sniffen C.J. Effect of exogenous growth hormone on lactational performance in high yielding dairy cows. J. Nutr. 111:1981;1662-1671.
9. Bauman D.E., Hard D.L., Crooker B.A., Partridge M.S., Garrick K., Sandles L.D., Erb H.N., Franson S.E., Hartnell G.F., Hintz R.L. Long-term evaluation of a prolonged-release formulation of n-methionyl bovine somatotropin. J. Dairy Sci. 72:1989;642-651.
10. Jenny B.F., Grimes L.W., Pardue F.E., Rock D.W., Patterson D.L. Lactational response of Jersey cows to bovine somatotropin administered daily or in a sustained-release formulation. J. Dairy Sci. 75:1992;3402-3407.
11. Cady S.M., Steber W.D., Fishbein R. Development of a sustained release delivery system for bovine somatotropin. Proc. Int. Symp. Control. Release Bioact. Mater. 16:1989;22-23.
12. Calsamiglia S., Hongerholt D.D., Crooker B.A., Stern M.D. Effect of fish meal and expeller-processed soybean meal fed to dairy cows receiving bovine somatotropin (Sometribove). J. Dairy Sci. 75:1992;2454-2462.
13. Chemical Marketing Reporter, FDA approves Monsanto's milk producing hormone, 15 November 1993, p. 20.
14. B. Hileman, FDA panel okays bovine growth hormone, Chem. Eng. News, 5 April, 1993, p. 5.
15. A. Lucas, bSt scores strong first-year growth, Chem. Week, 15 February 1995, p. 18.
16. WEFA Group, Projections, Eddystone, Pennsylvania, 1998.
17. J.W. Mitchell, Prolonged release of biologically active somatotropin, US Patent 5,013,713 (1991).
18. J.W. Mitchell, Methods of using prolonged release somatotropin compositions, US Patent 5,086,041 (1992).
19. J.W. Mitchell, Prolonged release of biologically active somatotropin, US Patent 5,411,951 (1995).
20. J.W. Mitchell, Prolonged release of biologically active somatotropin, US Patent 5,474,980 (1995).
21. Hartnell G.F., Franson S.E., Bauman D.E., Head H.H., Huber J.T., Lamb R.C., Madsen K.S., Cole W.J., Hintz R.L. Evaluation of sometribove in a prolonged-release system in lactating dairy cows - production responses. J. Dairy Sci. 74:1991;2645-2663.
22. European Pharma Law Centre, Possible progress for bovine somatotropin, 68 (1997) 5.
23. E. Kirschner, Monsanto wins approval for bovine hormone, Chem. Week, 17 November 1993, p. 9.
24. E. Kirschner, Monsanto ready for bST sales, Chem. Week, 15 February 1994, p. 10.
25. Anim. Pharm., Leading branded products by sales 1996, 9 (May 1997) 21.
26. Machlin L.J. Effect of porcine growth hormone on growth and carcass composition of the pig. J. Anim. Sci. 35:(4):1972;794-800.
27. Etherton T.D., Etherton K., Mills E.W. Recombinant bovine and porcine somatotropin: safety and benefits of these biotechnologies. J. Am. Diet. Assoc. 93:(2):1993;177-180.
28. Chung C.S., Etherton T.D., Wiggins J.P. Stimulation of swine growth by porcine growth hormone. J. Anim. Sci. 66:(1):1985;118-130.
29. Etherton T.D., Wiggins J.P., Evock C.M., Chung C.S., Rebhun J.F., Walton P.E., Steele N.C. Stimulation of pig growth performance by porcine growth hormone: determination of the dose-response relationship. J. Anim. Sci. 64:1987;433-443.
30. McNamara J.P., Brekke C.J., Jones R.W., Dalrymple R.H. Recombinant porcine somatotropin alters performance and carcass characteristics fed alternative feedstuffs. J. Anim. Sci. 69:1991;2273-2281.
31. Sorenson M.R., Oksbjerg N., Agergaard N., Petersen J.S. Tissue deposition rates in relation to muscle fibre and fat cell characteristics in lean female pigs (Sus scrofa) following treatment with porcine growth hormone (pGH). Comp. Biochem. Physiol. 113A:(2):1996;91-96.
32. K.N. Sivaramakrishnan, L.F. Miller, Controlled release delivery device for macromolecular proteins, International Patent Application PCT/US90/01340 (1990).
33. N.J. Kim, H.S. Cho, M.S. Song, Y.J. Choi, B.G. Rhee, Release-controlled implantable somatotropin composition, US Patent 5,662,917 (1997).
34. Hacker R.R., Deschutter A., Adeola O., Kasser T.R. Evaluation of long-term somatotropin implants in finishing pigs. J. Anim. Sci. 71:1993;564-570.
35. Azain M.J., Bullock K.D., Kasser T.R., Veenhuizen J.J. Relationship of mode of porcine somatotropin administration and dietary fat to the growth performance and carcass characteristics of finishing pigs. J. Anim. Sci. 70:1992;3086-3095.
36. Anim. Pharm., Australia first to approve PST, 293 (28 January 1994) 20.
37. Anim. Pharm. Rev., Biotech products steal the show in 1994, 317 (1994) 6-8.
38. Carlacci L., Chou K.C., Maggiora G.M. A heuristic approach to predicting the tertiary structure of bovine somatotropin. Biochemistry. 30:(18):1991;4389-4398.
39. Davio S.R., Hageman M.J. Characterization and formulation considerations for recombinantly derived bovine somatotropin. Wang Y.J., Pearlman R. Stability and Characterization of Protein and Peptide Drugs: Case Histories. 1993;59-89 Plenum Press, New York.
40. Manning M.C., Patel K., Borchardt R.T. Stability of protein pharmaceuticals. Pharm. Res. 6:(11):1989;903-918.
41. Chen T. Formulation concerns of protein drugs. Drug Dev. Ind. Pharm. 18:(11&12):1992;1311-1354.
42. Wang Y.-C.J., Hanson M.A. Parenteral formulations of proteins and peptides: stability and stabilizers. J. Parenter. Sci. Technol. 42:(Suppl.):1988;S4-S26.
43. Foster T.P. Protein/peptide veterinary formulations. Hardee G.E., Baggot J.D. Development and Formulation of Veterinary Dosage Forms. 1998;231-282 Marcel Dekker, Inc, New York.
44. Hageman M.J., Bauer J.M., Possert P.L., Darrington R.T. Preformulation studies oriented toward sustained delivery of recombinant somatotropins. J. Agric. Food Chem. 40:1992;348-355.
45. Cady S.M., Langer R. Overview of protein formulations for animal health applications. J. Agric. Food Chem. 40:1992;332-336.
46. Ferguson T.H., Thompson W.W., Moore D.L., Rodewald J.M. Chemical and physical characterization of somidobove, a recombinantly produced bovine somatotropin. Proc. Int. Symp. Control. Release Bioact. Mater. 15:1988;55a-55b.
47. Lewis U.J., Cheever E.V., Hopkins W.C. Kinetic study of the deamidation of growth hormone and prolactin. Biochim. Biophys. Acta. 214:1970;498-508.
48. Glaser C.B., Li C.H. Reaction of bovine growth hormone with hydrogen peroxide. Biochemistry. 13:(5):1974;1044-1047.
49. Cascone O., Biscoglio de Jimenez Bonino M., Santome J.A. Oxidation of methionine residues in bovine growth hormone by chloramine-T. Int. J. Pept. Prot. Res. 16:(4):1980;299-305.
50. Violand B.N., Schlittler M.R., Toren P.C., Siegel N.R. Formation of isoaspartate 99 in bovine and porcine somatotropins. J. Prot. Chem. 9:(1):1990;109-117.
51. Langley K.E., Berg T.F., Strickland T.W., Fenton D.M., Boone T.C., Wypych J. Recombinant-DNA-derived bovine growth hormone from Escherichia coli. 1. Demonstration that the hormone is expressed in reduced form, and isolation of the hormone in oxidized, native form. Eur. J. Biochem. 163:(2):1987;313-321.
52. Buckwalter B.L., Cady S.M., Shieh H.M., Chaudhuri A.K., Johnson D.F. Improvement in the solution stability of porcine somatotropin by chemical modification of cysteine residues. J. Agric. Food Chem. 40:(2):1992;356-362.
53. Lehrman S.R., Tuls J.L., Havel H.A., Haskell R.J., Putnam S.D., Tomich C.S. Site-directed mutagenesis to probe protein folding: evidence that the formation and aggregation of a bovine growth hormone folding intermediate are dissociable. Biochemistry. 30:(23):1991;5777-5784.
54. Charman S.A., McCrossin L.E., Charman W.N. Validation of a peptide map for recombinant porcine growth hormone and application to stability assessment. Pharm. Res. 10:(10):1993;1471-1477.
55. Brems D.N., Plaisted S.M., Havel H.A., Kauffman E.W., Stodola J.D., Eaton L.C., White R.D. Equilibrium denaturation of pituitary- and recombinant-derived bovine growth hormone. Biochemistry. 24:(26):1985;7662-7668.
56. Brems D.N., Plaisted S.M., Kauffman E.W., Havel H.A. Characterization of an associated equilibrium folding intermediate of bovine growth hormone. Biochemistry. 25:(21):1986;6539-6543.
57. Havel H.A., Kauffman E.W., Plaisted S.M., Brems D.N. Reversible self-association of bovine growth hormone during equilibrium unfolding. Biochemistry. 25:(21):1986;6533-6538.
58. Burger H.G., Edelhoch H., Condliffe P.G. The properties of bovine growth hormone. I. Behavior in acid solution. J. Biol. Chem. 241:(2):1966;449-457.
59. Puri N.K. Refolding of recombinant porcine growth hormone in a reducing environment limits in vitro aggregate formation. Fed. Eur. Biochem. Soc. 292:(1,2):1991;187-190.
60. Puri N.K., Cardamone M. A relationship between the starting secondary structure of recombinant porcine growth hormone solubilised from inclusion bodies and the yield of native (monomeric) protein after in vitro refolding. Fed. Eur. Biochem. Soc. 305:(3):1992;177-180.
61. Cardamone M., Puri N.K., Sawyer W.H., Capon R.J., Brandon M.R. A spectroscopic and equilibrium binding analysis of cationic detergent-protein interactions using soluble and insoluble recombinant porcine growth hormone. Biochim. Biophys. Acta. 1206:1994;71-82.
62. Bell L.N., Hageman M.J., Bauer J.M. Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin. Biopolymers. 35:(2):1995;201-209.
63. Randall C.S., Malefyt T.R., Sternson L.A. Approaches to the analysis of peptides. Lee V.H.L. Peptide and Protein Drug Delivery. 1991;203-246 Marcel Dekker, New York.
64. Pearlman R., Nguyen T.H. Analysis of protein drugs. Lee V.H.L. Peptide and Protein Drug Delivery. 1991;247-301 Marcel Dekker, Inc, New York.
65. Hanson M.A., Rouan S.K.E. Introduction to formulation of protein and pharmaceuticals. Ahern T.J., Manning M.C. Stability of Protein Pharmaceuticals: Part B: in Vivo Pathways of Degradation and Strategies For Protein Stabilization. 1992;209-233 Plenum Press, New York.
66. Wallis M. The primary structure of bovine growth hormone. FEBS Lett. 35:(1):1973;11-14.
67. Santome J.A., Dellacha J.M., Paladini A.C., Pena C., Biscoglio M.J., Daurat S.T., Poskus E., Wolfenstein C.E. Primary structure of bovine growth hormone. Eur. J. Biochem. 37:(1):1973;164-170.
68. Graf L., Li C.H. On the primary structure of pituitary bovine growth hormone. Biochem. Biophys. Res. Commun. 56:(1):1974;168-175.
69. Secchi C., Borromeo V. Structure and function of bovine growth hormone, bovine growth hormone as an experimental model for studies of protein-protein interactions. J. Chromatogr. B. 688:1997;161-177.
70. Holladay L.A., Hammonds R.G., Puett D. Growth hormone conformation and conformation equilibria. Biochemistry. 13:(8):1974;1653-1661.
71. Sonenberg M., Beychok S. Circular dichroism studies of biologically active growth hormone preparations. Biochim. Biophys. Acta. 229:1971;88-101.
72. Havel H.A., Chao R.S., Haskell R.J., Thamann T.J. Investigations of protein structure with optical spectroscopy: bovine growth hormone. Anal. Chem. 61:(7):1989;642-650.
73. Oeswein J.Q., Shire S.J. Physical biochemistry of protein drugs. Lee V.H.L. Peptide and Protein Drug Delivery. 1991;167-202 Marcel Dekker, Inc, New York.
74. Stodola J.D., Walker J.S., Dame P.W., Eaton L.C. High-performance size-exclusion chromatography of bovine somatotropin. J. Chromatogr. 357:(3):1986;423-428.
75. Hartman P.A., Stodola J.D., Harbour G.C., Hoogerheide J.G. Reversed-phase high-performance liquid chromatography peptide mapping of bovine somatotropin. J. Chromatogr. 360:(2):1986;385-395.
76. Chang J.P., Kiehl D.E., Kennington A. Separation and characterization of the tryptic peptide mapping of recombinant bovine growth hormone by reversed-phase high-performance liquid chromatography electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 11:1997;1266-1270.
77. Tsuji K. Evaluation of sodium dodecyl sulfate non-acrylamide, polymer gel filled capillary electrophoresis for molecular size separation of recombinant bovine somatotropin. J. Chromatogr. A. 652:(1):1993;139-147.
78. Haro L.S., Collier R.J., Talamantes F.J. Homologous somatotropin radioreceptor assay utilizing recombinant bovine growth hormone. Mol. Cell. Endocrinol. 38:1984;109-116.
79. Secchi C., Biondi P.A., Berrini A., Simonic T., Ronchi S. A biotin-avidin sandwich enzyme-linked immunosorbent assay of growth hormone in bovine plasma. J. Immunol. Methods. 110:(1):1988;123-128.
80. Reynaert R., Franchimont P. Radioimmunoassay of bovine growth hormone. Ann. Endocrinol. 35:(2):1974;139-148.
81. MacKenzie N.E., Plaisted S.M., Brems D.N. Proton nuclear magnetic resonance study of the histidine residues of pituitary bovine growth hormone. Biochim. Biophys. Acta. 994:(2):1989;166-171.
82. Gooley P.R., Plaisted S.M., Brems D.N., Mackenzie N.E. Determination of local conformational stability in fragment 96-133 of bovine growth hormone by high-resolution H NMR spectroscopy. Biochemistry. 27:(2):1988;802-809.
83. Wingfield P.T., Graber P., Rose K., Simona M.G., Hughes G.J. Chromatofocusing of N-terminally processing forms of proteins. Isolation and characterization of two forms of interleukin-1 beta and of bovine growth hormone. J. Chromatogr. 387:1987;291-300.
84. Burton J.L., McBride B.W., Block E., Glimm D.R., Kennelly J.J. A review of bovine growth hormone. Can. J. Anim. Sci. 74:1994;167-201.
85. Cole W.J., Eppard P.J., Boysen B.G., Madsen K.S., Sorbet R.H., Miller M.A., Hintz R.L., White T.C., Ribelin W.E., Hammond B.G., Collier R.J., Lanza G.M. Response of dairy cows to high doses of a sustained-release bovine somatotropin administered during two lactations: 2. health and reproduction. J. Dairy Sci. 75:1992;111-123.
86. Eppard P.J., Bauman D.E., Curtis C.R., Erb H.N., Lanza G.M., DeGeeter M.J. Effect of 188-day treatment with somatotropin on health and reproductive performance of lactating dairy cows. J. Dairy Sci. 70:1987;582-591.
87. Posilac Package Insert, Monsanto Company (1993).
88. Leonard M., Gallo M., Gallo G., Block E. Effects of a 28-day sustained-release formulation of recombinant bovine somatotropin (rbST) administered to cows over two consecutive lactations. Can. J. Anim. Sci. 70:1990;795-809.
89. Smith D.E., Skalnik J.R., Skalnik P.C. The bSt debate: the relationship between awareness and acceptance of technological advances. Agric. Human Values. 14:1997;59-66.
90. Juskevich J.C., Guyer C.G. Bovine growth hormone: human food safety evaluation. Science. 249:1990;875-884.
91. Official J. European Communities, Council decision of 20 December 1994 amending decision 90/218/EEC concerning the placing on the market and administration of bovine somatotrophin (BST) L366/19-20.
92. V.D. Arendt, Composition and method for reducing vial breakage during lyophilization, US Patent 5,169,834 (1992).
93. E.J. Hamilton, B.D. Burleigh, Stabilization of growth promoting hormones, European Patent Application 87307406.6 (1987).
94. M.S. Hageman, Sustained release protein formulations, International Patent Application WO94/06452 (1994).
95. M.J. Hageman, P.L. Possert, Aqueous prolonged release formulation, International Patent Application WO95/19787 (1995).
96. T.H. Ferguson, R.G. Harrison, L. Moore, Injectable sustained release formulation, US Patent 4,977,140 (1990).
97. W. Steber, Stable compositions for parenteral administration and method of making same, European Patent Application 0448930A1 (1991).
98. M. Maniar, A.J. Domb, Controlled release microparticle delivery system for proteins, International Patent Application WO92/14449 (1992).
99. W. Steber, R. Fishbein, S.M. Cady, Compositions for parenteral administration and their use, European Patent Application 0257368A1 (1987).
100. M.J. Azain, K.E. Eigenberg, T.R. Kasser, M.J. Sabacky, Method for prolonged release of somatotropin, European Patent Application 90202047.8 (1990).
101. Ron E., Turek T., Mathiowitz E., Chasin M., Langer R. Release of polypeptides from poly(anhydride) implants. Proc. Int. Symp. Control. Release Bioact. Mater. 16:1989;338-339.
102. E. Ron, M. Chasin, T. Turek, R. Langer, Polyanhydride bioerodible controlled release implants for administration of stabilized growth hormone, US Patent 5,122,367 (1992).
103. M.D. Shalati, R. Viswanatha, Sustained release implant and method for preparing same, US Patent 4,761,289 (1988).
104. Sivaramakrishnan K.N., Rahn S.L., Moore B.M., O'Neil J. Sustained release of bovine somatotropin from implants. Proc. Int. Symp. Control. Release Bioact. Mater. 16:1989;14-15.
105. J.S. Kent, Cholesterol matrix delivery system for sustained release of macromolecules, US Patent 4,452,775 (1984).
106. A.M. Janski, R.-D. Yang, Controlled release implants for administration of recombinant growth hormones, European Patent Application 86305431.8 (1987).
107. A.M. Janski, R.-D. Yang, Cylindrical implants for the controlled release of growth hormones, US Patent 4,786,501 (1988).
108. Caperna T.J., Steele N.C., Evock-Clover C.M., Brocht D., McMurtry J.P., Rosebrough R.W. Acute effects of administration of porcine growth hormone on circulating levels of hormones and metabolites in 20-, 40-, and 60-kilogram gilts. J. Anim. Sci. 71:1993;897-905.
109. Evock C.M., Etherton T.D., Chung C.S., Ivy R.E. Pituitary porcine growth hormone (pGH) and a recombinant pGH analog stimulate pig growth performance in a similar manner. J. Anim. Sci. 66:1988;1928-1941.
110. Wray-Cahen D., Ross D.A., Bauman D.E., Boyd R.D. Metabolic effects of porcine somatotropin: nitrogen and energy balance and characterization of the temporal pattern of blood metabolites and hormones. J. Anim. Sci. 69:1991;1503-1514.
111. McLaren D.G., Bechtel P.J., Grebner G.L., Novakofski J., McKeith F.K., Jones R.W., Dalrymple R.H., Easter R.A. Dose response in growth of pigs injected daily with porcine somatotropin from 57 to 103 kilograms. J. Anim. Sci. 68:1990;640-651.
112. J.L. Martin, J.F. Kramer, Prolonged release of growth promoting hormones, Australian Patent Application 61092/86 (1986).
113. N.J. Kim, B.G. Rhee, H.S. Cho, A composition durably releasing bioactive polypeptides, Australian Patent Application 70937/91 (1991).
114. S.N. Raman, M.W. Gray, R.L. Smith, Compositions and processes for the sustained release of drugs, US Patent 5,328,697 (1994).
115. Wyse J.W., Takahashi Y., DeLuca P.P. Instability of porcine somatotropin in polyglycolic acid microspheres. Proc. Int. Symp. Control. Release Bioact. Mater. 16:1989;334-335.
116. N.J. Kim, H.S. Cho, M.S. Song, Y.J. Choi, B.G. Rhee, Release-controlled implantable somatotropin composition, Australian Patent Application 52718/93 (1993).
117. Knight C.D., Kasser T.R., Swenson G.H., Hintz R.L., Azain M.J., Bates R.O., Cline T.R., Crenshaw J.D., Cromwell G.L., Hedrick H.B., Jones S.J., Kropf D.H., Lewis A.J., Mahan D.C., McKeith F.M., Laughlin C.L., Nelssen J.L., Novakofski J.E., Orcutt M.W., Parrett N.A. The performance and carcass composition responses of finishing swine to a range of porcine somatotropin doses in a 1-week delivery system. J. Anim. Sci. 69:1991;4678-4689.
118. M.J. Azain, K.E. Eigenberg, T.R. Kasser, M.J. Sabacky, Somatotropin prolonged release, US Patent 4,863,736 (1989).
119. A.M. Janski, S.M. Drengler, Method for stabilising proteins, European Patent Application 88302317.8 (1988).
120. S.N. Raman, R.B. DePrince, A. Blum, Delayed release for transition metal/protein complexes, International Patent Application PCT/US93/00274 (1993).
121. R.B. DePrince, R. Viswanatha, Stabilized porcine growth hormone, US Patent 4,765,980 (1988).
122. W.D. Steber, S.M. Cady, D.F. Johnson, T. Rice, Implant compositions containing a biologically active protein, peptide or polypeptide, European Patent Application 92107278.1 (1992).
123. J.B. Eckenhoff, J.A. Magruder, J.R. Peery, J.C. Wright, Device compromising means for protecting and dispensing fluid sensitive medicament, US Patent 4,855,141 (1989).
124. J.B. Eckenhoff, J.A. Magruder, R. Cortese, J.R. Peery, J.C. Wright, Method for delivering somatotropin to an animal, US Patent 4,959,218 (1990).
125. Becker B.A., Knight C.D., Buonomo F.C., Jesse G.W., Hedrick H.B., Baile C.A. Effect of a hot environment on performance, carcass characteristics, and blood hormones and metabolites of pigs treated with porcine somatotropin. J. Anim. Sci. 70:1992;2732-2740.
126. Rosemberg E., Thonney M.L., Butler W.R. The effects of bovine growth hormone and thyroxine on growth rate and carcass measurements in lambs. J. Anim. Sci. 67:1989;3300-3312.
127. Ludri R.S., Upadhyay R.C., Singh M., Guneratne J.R.M., Basson R.P. Milk production in lactating buffalo receiving recombinantly produced bovine somatotropin. J. Dairy Sci. 72:1989;2283-2287.
128. Stelwagen K., Grieve D.G., Walton J.S., Ball J.L., McBride B.W. Effect of prepartum bovine somatotropin in primigravid ewes on mammogenesis, milk production and hormone concentrations. J. Dairy Sci. 76:1993;992-1001.
129. McLean E., Devlin R.H., Byatt J.C., Clarke W.C., Donaldson E.M. Impact of a controlled release formulation of recombinant bovine growth hormone upon growth and seawater adaptation in coho (Oncorhynchus kisutch) and chinook (Oncorhynchus tshawytscha) salmon. Aquaculture. 156:1997;113-128.
130. Buonomo F.C., Baile C.A. Recombinant bovine somatotropin stimulates short term increases in growth rate and insulin-like growth factor-I (IGF-I) in chickens. Dom. Anim. Endocrinol. 5:(3):1988;219-229.
131. Dean C.E., Hargis B.M., Burke W.H., Hargis P.S. Alterations in thyroid metabolism are associated with improved posthatch growth of chickens administered bovine growth hormone in ovo. Growth Dev. Aging. 57:1993;57-72.
132. 2 terminus. J. Clin. Invest. 78:1986;906-913.
133. Martin R.A., Cleary D.L., Guido D.M., Zurcher-Neely H.A., Kubiak T.M. Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity? Biochim. Biophys. Acta. 1164:(3):1993;252-260.
134. 2 and its deamidation products by 2D NMR. Int. J. Pept. Prot. Res. 42:1993;24-32.
135. 15-substituted analogs of bovine growth hormone releasing factor (bGRF) with enhanced metabolic stability and improved in vivo bioactivity. J. Med. Chem. 36:1993;888-897.
136. 2 from a PLA/GA matrix. J. Control. Release. 24:1993;237-246.
137. Foster T.P., Moseley W.M., Caputo J.F., Alaniz G.R., Leatherman M.W., Yu X., Claflin W.H., Reeves D.R., Cleary D.L., Zantello M.R., Krabill L.F., Wiest J.R. Sustained elevated serum somatotropin concentrations in Holstein steers following subcutaneous delivery of a growth hormone releasing factor analog dispersed in water, oil or microspheres. J. Control. Release. 47:1997;91-99.
138. M. Ankersen, Compounds with growth hormone releasing properties, International Patent Application WO96/24587 (1996).
139. Aston R., Holder A.T., Ivanyi J., Bomford R. Enhancement of bovine growth hormone activity in vivo by monoclonal antibodies. Mol. Immunol. 24:(2):1987;143-150.
140. Zhang R.-J., Lumanglas A.A., Wang B.S. Modulation of the effectiveness of growth hormone with a monoclonal antibody. Neuroimmunomodulation. 1:1994;343-349.
141. Wang B.S., Lumanglas A.A., Shieh H.-M., Corbett M.J., Zhang R.-J., Kraft L.A. Immunological effect of a synthetic growth hormone peptide on the growth performance in swine. Mol. Immunol. 33:(7/8):1996;609-614.